NOTICE OF EXTRAORDINARY GENERAL MEETING IN NEXAM CHEMICAL HOLDING AB (PUBL)

Nexam Chemical convenes an Extraordinary General Meeting on 19 January 2026 to approve a Board resolution (22 Dec 2025) for a rights issue of up to 21,577,544 shares at SEK 2.40 each (max share capital increase SEK 414,952.769242), with record date 22 January 2026 and subscription period 26 January–9 February 2026. The meeting will also consider authorisations to issue shares to guarantors (at VWAP not below SEK 2.40) and an over-allotment facility of up to 6,250,000 shares at SEK 2.40; current registered shares total 80,915,798 and items on guarantor/over-allotment require a two-thirds majority.

Analysis

Market structure: The rights issue (max ~21.58m new shares at SEK2.40 plus possible 6.25m over-allotment) increases free float by up to ~34% of existing shares but dilutes ownership by ~25.6% (new/(old+new)). Short-term pressure likely around record date (22 Jan) and during subscription 26 Jan–9 Feb as holders sell to fund subscriptions; long-term winners are creditors/operations if proceeds (~SEK52–66.8m gross) fund commercial scaling and margin-accretive projects.

Risk assessment: Immediate risk (days–weeks) is price gap/dilution and potential failure of underwriting or guarantee-conversion mechanics; medium-term (1–6 months) risks include execution risk turning proceeds into revenue and regulatory screening (Screening of Foreign Direct Investments Act) delaying allocations. Tail risks: guarantor-share issuance at VWAP mechanics could swamp market if VWAP >> SEK2.40 or if Inspectorate blocks large foreign allocations, causing >30% downside.

Trade implications: Primary alpha is event arbitrage around subscription window and VWAP-determined guarantor issue. If you hold Nexam (NEXAM / NEXAM.ST), exercising rights to avoid dilution is mechanically best; non-holders can buy rights or short pre-ex-date weakness. Volatility should rise; use short-dated puts or put spreads for downside protection and consider covered-call income on positions post-subscription once float stabilizes.

Contrarian angles: Consensus focuses on dilution; market may underprice execution optionality — if management converts proceeds into two new contracts or >20% revenue growth within 12 months, stock could rerate. Conversely, overhang from guarantor/top-guarantee allocations is a rehypothecation risk: if guarantors flip shares immediately, selling could persist for 3–6 months. VWAP path during 26 Jan–9 Feb is the single highest-value signal to time trades.

Key Decisions for Investors

• If long Nexam (NEXAM / NEXAM.ST): exercise subscription rights pro rata during 26 Jan–9 Feb to avoid dilution; allocate cash equal to 2.4 SEK * (your current shares * 4/15) to maintain ownership. Target: maintain exposure up to current weight; reevaluate 3 months post-close against revenue ramp.
• Opportunistic small long (2–3% NAV): initiate after subscription window closes if share price trades ≥15% below the theoretical ex-rights price (by mid-February); take profits or reassess at 6–12 month horizon if company posts tangible commercial wins or revenue growth >20% YoY.
• Short/hedge (1–2% NAV): ahead of record date, establish downside protection via buying 3–6 month put spreads on NEXAM (buy 15% OTM put, sell 30% OTM put) sized to cover existing long exposure; if options illiquid, short up to 1–2% NAV directly and cover after Feb expiry.
• Event-monitor action: track VWAP during 26 Jan–9 Feb (sets guarantor price). If VWAP > SEK2.80 (≈+16% above issue price), reduce short positions and increase long conviction; if VWAP < SEK2.40 floor is binding and selling pressure persists, increase hedges by 50% within 48 hours of announcement.
• Governance/regulatory trigger: if any investor allocation would trigger notification under the Screening of Foreign Direct Investments Act, pause new buys above 5% ownership until Inspectorate ruling (typically 30–90 days) — avoid unregistered large blocks that could be locked or forced to divest.